These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
890 related articles for article (PubMed ID: 29686424)
1. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424 [TBL] [Abstract][Full Text] [Related]
2. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB Cells; 2021 Dec; 10(12):. PubMed ID: 34944068 [No Abstract] [Full Text] [Related]
3. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195 [TBL] [Abstract][Full Text] [Related]
5. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160 [TBL] [Abstract][Full Text] [Related]
6. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681 [TBL] [Abstract][Full Text] [Related]
7. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Kosaka T; Tanizaki J; Paranal RM; Endoh H; Lydon C; Capelletti M; Repellin CE; Choi J; Ogino A; Calles A; Ercan D; Redig AJ; Bahcall M; Oxnard GR; Eck MJ; Jänne PA Cancer Res; 2017 May; 77(10):2712-2721. PubMed ID: 28363995 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844 [TBL] [Abstract][Full Text] [Related]
9. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113 [TBL] [Abstract][Full Text] [Related]
11. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Elamin YY; Robichaux JP; Carter BW; Altan M; Tran H; Gibbons DL; Heeke S; Fossella FV; Lam VK; Le X; Negrao MV; Nilsson MB; Patel A; Vijayan RSK; Cross JB; Zhang J; Byers LA; Lu C; Cascone T; Feng L; Luthra R; San Lucas FA; Mantha G; Routbort M; Blumenschein G; Tsao AS; Heymach JV Cancer Cell; 2022 Jul; 40(7):754-767.e6. PubMed ID: 35820397 [TBL] [Abstract][Full Text] [Related]
12. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Wu JY; Yu CJ; Shih JY Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643 [TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Robichaux JP; Elamin YY; Vijayan RSK; Nilsson MB; Hu L; He J; Zhang F; Pisegna M; Poteete A; Sun H; Li S; Chen T; Han H; Negrao MV; Ahnert JR; Diao L; Wang J; Le X; Meric-Bernstam F; Routbort M; Roeck B; Yang Z; Raymond VM; Lanman RB; Frampton GM; Miller VA; Schrock AB; Albacker LA; Wong KK; Cross JB; Heymach JV Cancer Cell; 2019 Oct; 36(4):444-457.e7. PubMed ID: 31588020 [TBL] [Abstract][Full Text] [Related]
15. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
19. Poziotinib in Non-Small-Cell Lung Cancer Harboring Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401 [TBL] [Abstract][Full Text] [Related]
20. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]